Universal Vision Biotechnology Co., Ltd.

Universal Vision Biotechnology Co., Ltd.

TTPEX:3218
123.00
TWD
-1.50
(-1.20%)
13.59EPS
10.14P/E
11.61BMarket Cap
Mar 11Next Earn
Universal Vision Biotechnology Co., Ltd.
TPEX:3218
(Taipei Exchange)

Recent

price

123.00

P/E

ratio

10.14

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
13.67
15.64
10.15
12.17
13.13
13.48
14.58
13.34
14.1
16.75
24.23
31.06
41.24
48.18
49.91
49.62
50.43
Revenue per Share
-0.85
0.53
-1.2
1.15
1.35
1.08
1.25
1.48
1.91
2.81
5.7
7.03
10.04
12.34
12.57
12.31
13.51
Basic EPS, GAAP
-4.41
0.42
-1.71
1.19
0.37
-1.36
1.1
1.24
0.79
2.12
6.24
6.88
9.15
12.74
14.58
13.01
15.4
Free Cash Flow per Basic Share
- -
- -
0.29
- -
0.88
0.92
0.99
1.08
1.08
1.12
1.8
3.77
4.49
5.66
7
7.5
- -
Dividend per Share
11.99
14.96
13.42
14.6
15.15
15.28
15.41
16.61
17.43
18.78
22.59
25.83
31.45
37.51
42.75
47.48
45.72
Book Value per Share
11.99
14.92
13.37
14.56
15.13
15.21
15.33
16.55
17.37
18.7
22.28
25.52
31.14
37.23
42.48
47.41
45.64
Tangible Book Value per Share
51
53
76
75
75
75
74
81
85
85
85
85
85
85
85
85
85
Basic Weighted Avg Shares
692
832
767
916
988
1,014
1,073
1,082
1,195
1,419
2,053
2,632
3,494
4,082
4,228
4,204
4,274
Sales/Revenue/Turnover
0.2
4.71
-13.73
9.79
9.92
9.09
10.6
11.91
11.7
17.4
29.05
29.21
31.16
32.24
33.12
32.76
31.2
Operating Margin (%)
66
62
77
86
98
109
121
126
128
245
264
320
372
446
521
544
567
Depreciation Expense
-43
28
-91
86
102
81
92
120
161
238
483
595
851
1,045
1,065
1,043
1,145
Net Income, GAAP
- -
17.35
- -
14.73
16.76
19.2
17
23.54
27.34
24.83
19.59
19.98
20.51
19.31
20.32
21.63
18.45
Effective Tax Rate (%)
-6.23
3.37
-11.84
9.44
10.28
7.99
8.56
11.09
13.51
16.77
23.54
22.62
24.34
25.6
25.18
24.8
26.78
Profit Margin (%)
233
642
483
561
560
474
445
844
811
695
889
1,047
1,249
1,557
1,751
1,972
506
Working Capital
62
34
16
- -
- -
- -
- -
- -
- -
392
329
628
633
613
784
786
992
LT Debt
664
1,134
1,011
1,099
1,141
1,150
1,160
1,583
1,609
1,695
2,039
2,328
2,829
3,343
3,756
4,159
3,904
Total Equity
- -
2.82
- -
6.32
6.02
4.92
6.51
6.27
5.79
8.99
18.98
20.8
24.81
26.36
24.09
20.94
20.75
Return on Invested Capital (%)
- -
3.04
- -
7.61
7.77
5.72
6.62
9.78
11.87
14.53
19.92
20.55
25.15
26.87
24.54
20.93
22.72
Return on Capital (%)
-6.4
3.11
-8.47
8.2
9.07
7.08
7.95
9.36
11.2
15.51
27.57
29.03
35.05
35.78
31.32
27.28
31.66
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
278
220
515
LT Borrowings
- -
- -
- -
LT Finance Leases
786
908
992
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
85
85
85
Market Capitalization
12,370
11,226
11,607

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
3,001
3,303
1,899
Cash, Cash Equivalents & STI
2,103
2,405
1,029
Accounts Receivable, Net
514
514
505
Inventories
304
302
290
Total Current Liabilities
1,029
1,734
1,393
Payables & Accruals
- -
- -
- -
ST Debt
278
220
515
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.16%
15.38%
10.74%
Free Cash Flow
26.05%
17.24%
-10.72%
Net Income, GAAP
31.77%
17.75%
-2.07%
Sales/Revenue/Turnover
16.13%
16.16%
-0.57%
Total Cash Common Dividend
27.95%
37.17%
7.14%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,071
1,039
1,080
1,038
4,228
2025
1,123
1,023
1,025
1,033
4,204
2026
1,090
1,126
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3.59
3.28
2.88
2.82
12.57
2025
4.28
0.5
4.05
3.47
12.31
2026
3.31
2.67
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
7
2025
- -
- -
- -
- -
7.5
2026
- -
- -
- -
- -
- -
Business
Universal Vision Biotechnology Co., Ltd. (3218.TWO) operates as a leading provider of comprehensive vision care services and products across Taiwan and mainland China, specializing in ophthalmic medical treatments, optical retail, and biotechnology solutions for eye health. Founded in 1994 by ophthalmologists Dr. Pi-Jung Lin and Dr. Shu-Fang Ou and headquartered in Taipei, Taiwan, the company publicly listed on the Taipei Exchange in 2004 and manages a network of approximately 25 affiliated eye clinics and 38 optical stores in Taiwan alongside 10 eye clinics and 10 optical stores in China, primarily concentrated in eastern regions such as Shanghai, Ningbo, Suzhou, and Hangzhou. Its core offerings encompass advanced laser vision correction procedures including VISX excimer laser refractive surgery, SMILE, SMILE PRO, and Presbyond MEL90 excimer laser for presbyopia; femtosecond laser-assisted cataract surgeries with Alcon LenSx; intraocular lens implants; myopia control programs; eye plastic and micro cosmetic surgeries; aesthetic medicine consulting; hospital management, optometric, and technical consultancy services; leasing of medical devices; medical and scientific prescription eyeglasses; sunglasses, fashionable and reading glasses, progressive lenses for presbyopia; contact lenses for myopia, hyperopia, presbyopia, and astigmatism; and nutritional supplements for eye protection such as Universal lutein products, which have received SNQ, Superior Taste Award, and Gold Award by Monde Selection certifications. The company maintains the "e-Universal" brand for licensed eye clinics and "Universal Optical" for self-owned eyewear channels, delivering one-stop vision care integrating B2B ophthalmology equipment and B2C optometry services while targeting consumers seeking lifelong eye health, beauty, and corrective solutions. Recent developments include the introduction of the SMILE PRO femtosecond laser surgery instrument ahead of the Asia Pacific region and the Presbyond MEL90 excimer laser for presbyopia; establishment of new facilities such as Hangzhou Gongshu Universal Eye Center and Myopia Control Center for Teenagers at Ningbo Universal Eye Center; acquisition of Suzhou Haiweishi Eye Clinic; expansion of the Taiwan brand network to 25 affiliated eye clinics; upgrades to AA rating in MSCI ESG evaluation, Top 5% rankings in TPEx Corporate Governance Evaluations for 2022 and 2023, and receipt of the TPEx Mid-tier Partner Award, Bronze Award in TCSA Taiwan Corporate Sustainability Awards, Golden Service Certification, and selection as a Model Business Entity for Uniform Invoice Usage; and ongoing JCI accreditations for affiliated clinics marking the fifth consecutive achievement alongside multiple SNQ recognitions for supplements and operational partnerships with hospitals like Ningbo First Hospital and Hangzhou Dian Holding Co., Ltd. via Taixue Medical Investment Management (Zhejiang) Co., Ltd.